

## NANOFORM SECURES €5 MILLION R&D LOAN FROM BUSINESS FINLAND TO ADVANCE CLINICAL DEVELOPMENT OF NANOAPALUTAMIDE

Nanoform Finland Plc | Press Release | June 19, 2025 at 09:00:00 EEST

**Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), a leading nanoparticle medicine performance-enhancing company, is pleased to announce that Business Finland has approved a €5 million research and development loan to support the clinical development of nanoapalutamide, Nanoform's proprietary nanocrystalline formulation of apalutamide.**

"We are grateful for Business Finland's continued support and confidence in our technology and vision", said Prof. Edward Hæggström, CEO of Nanoform. "This funding enables us to further accelerate the clinical validation of our nanoformulation platform and bring a more patient-friendly and sustainable alternative to market."

Nanoapalutamide is one of Nanoform's several product co-development programs for value-added medicines and the next-generation reformulation of Johnson & Johnson's Erleada® (apalutamide). By leveraging Nanoform's proprietary technology platforms, the nanoformulated version enables a significantly higher drug load, allowing for a substantially smaller tablet size. This innovation is designed to improve patient adherence and reduce pill burden - an important consideration for prostate cancer patients.

The €5 million loan covers up to 50% of the costs associated with the clinical development programme through to the pivotal bioequivalence study. Up to 30% of the loan funding granted for the project is paid as an advance at the beginning of the project, and the remaining loan amount based on realized costs. The interest rate on the loan is three percentage points below the base interest rate, or at least one percent, and no collateral is required. The loan period is ten years, of which five are instalment-free. If the project fails or its results cannot be used in Nanoform's business operations, part of the loan may remain uncollected.

The nanoapalutamide programme is part of Nanoform's broader "Small as an Ingredient" initiative, which aims to replace conventional amorphous solid dispersion (ASD) technologies with more sustainable and patient friendly nanocrystalline solutions. There are ~50 marketed ASD medicines globally that sell for ~\$50bln annually, and many more candidates in development phase.

For further information, please contact:

Peter Hänninen, General Counsel & Chief Development Officer

[peter.hanninen@nanoform.com](mailto:peter.hanninen@nanoform.com)

+358 (0)50 353 0408

Henri von Haartman, Director of Investor Relations

[hvh@nanoform.com](mailto:hvh@nanoform.com)

+46 (0)7686 650 11

#### About Nanoform

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 (0)73 856 42 65, [certifiedadviser@carnegie.se](mailto:certifiedadviser@carnegie.se). For more information, please visit [www.nanoform.com](http://www.nanoform.com).

#### Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words "may", "will", "could", "would", "should", "expect", "plan", "anticipate", "intend", "believe", "estimate", "predict", "project", "potential", "continue", "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2024 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

#### Attachments

**NANOFORM SECURES €5 MILLION R&D LOAN FROM BUSINESS FINLAND TO ADVANCE CLINICAL DEVELOPMENT OF NANOAPALUTAMIDE**